BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1261 related articles for article (PubMed ID: 26511749)

  • 1. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years.
    Toner L; Papa N; Aliyu SH; Dev H; Lawrentschuk N; Al-Hayek S
    World J Urol; 2016 Jul; 34(7):1031-7. PubMed ID: 26511749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern -A hospital based cross sectional study.
    Fernando MM; Luke WA; Miththinda JK; Wickramasinghe RD; Sebastiampillai BS; Gunathilake MP; Silva FH; Premaratna R
    BMC Infect Dis; 2017 Feb; 17(1):138. PubMed ID: 28187754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period.
    Burgess DS; Hall RG; Lewis JS; Jorgensen JH; Patterson JE
    Pharmacotherapy; 2003 Oct; 23(10):1232-7. PubMed ID: 14594340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
    Aris P; Boroumand MA; Rahbar M; Douraghi M
    Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low frequency of antibiotic resistance among urine isolates of Escherichia coli in the community, despite a major hospital outbreak with Klebsiella pneumoniae producing CTX-M-15 in Uppsala County.
    Lindbäck H; Lindbäck J; Sylvan S; Melhus A
    Scand J Infect Dis; 2010 Apr; 42(4):243-8. PubMed ID: 20085420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antibiotic resistance rates of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital].
    Akyar I
    Mikrobiyol Bul; 2008 Oct; 42(4):713-5. PubMed ID: 19149097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefoxitin-based antibiotic therapy for extended-spectrum β-lactamase-producing Enterobacteriaceae prostatitis: a prospective pilot study.
    Demonchy E; Courjon J; Ughetto E; Durand M; Risso K; Garraffo R; Roger PM
    Int J Antimicrob Agents; 2018 Jun; 51(6):836-841. PubMed ID: 29378342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary Tract Infections in Kidney Transplant Patients Due to Escherichia coli and Klebsiella pneumoniae-Producing Extended-Spectrum β-Lactamases: Risk Factors and Molecular Epidemiology.
    Espinar MJ; Miranda IM; Costa-de-Oliveira S; Rocha R; Rodrigues AG; Pina-Vaz C
    PLoS One; 2015; 10(8):e0134737. PubMed ID: 26237422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nosocomial and community infections due to class A extended-spectrum β-lactamase (ESBLA)-producing Escherichia coli and Klebsiella spp. in southern Brazil.
    Wollheim C; Guerra IM; Conte VD; Hoffman SP; Schreiner FJ; Delamare AP; Barth AL; Echeverrigaray S; Costa SO
    Braz J Infect Dis; 2011; 15(2):138-43. PubMed ID: 21503400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging Perils of Extended Spectrum
    Parajuli NP; Maharjan P; Joshi G; Khanal PR
    Biomed Res Int; 2016; 2016():1782835. PubMed ID: 28119921
    [No Abstract]   [Full Text] [Related]  

  • 13. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia.
    Martínez JA; Aguilar J; Almela M; Marco F; Soriano A; López F; Balasso V; Pozo L; Mensa J
    J Antimicrob Chemother; 2006 Nov; 58(5):1082-5. PubMed ID: 16950822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An observational study on bloodstream extended-spectrum beta-lactamase infection in critical care unit: incidence, risk factors and its impact on outcome.
    Nasa P; Juneja D; Singh O; Dang R; Singh A
    Eur J Intern Med; 2012 Mar; 23(2):192-5. PubMed ID: 22284253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae isolated in a rural hospital.
    Basak S; Mallick SK; Bose S
    J Indian Med Assoc; 2009 Dec; 107(12):855-8. PubMed ID: 20509468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program.
    Bhavnani SM; Ambrose PG; Craig WA; Dudley MN; Jones RN;
    Diagn Microbiol Infect Dis; 2006 Mar; 54(3):231-6. PubMed ID: 16423491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities.
    Saltoglu N; Karali R; Yemisen M; Ozaras R; Balkan II; Mete B; Tabak F; Mert A; Hondur N; Ozturk R
    Int J Clin Pract; 2015 Jul; 69(7):766-70. PubMed ID: 25683907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phenotypic and molecular identification of extended-spectrum beta-lactamase (ESBL) TEM and SHV produced by clinical isolates Escherichia coli and Klebsiella spp. in hospitals].
    González Mesa L; Ramos Morí A; Nadal Becerra L; Morffi Figueroa J; Hernández Robledo E; Alvarez AB; Marchena Bequer JJ; González Alemán M; Villain Plous C
    Rev Cubana Med Trop; 2007; 59(1):52-8. PubMed ID: 23427419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
    Titelman E; Iversen A; Kalin M; Giske CG
    Microb Drug Resist; 2012 Apr; 18(2):189-92. PubMed ID: 22204597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.